{Reference Type}: Journal Article
{Title}: Atherogenic Dyslipidemias: Unmet Needs and the Therapeutic Potential of Emerging and Novel Approaches and Drugs.
{Author}: Romandini A;Baldassarre D;Genovese S;Capri S;Pompilio G;Scatigna M;Werba JP;
{Journal}: Pharmaceuticals (Basel)
{Volume}: 16
{Issue}: 2
{Year}: 2023 Jan 24
{Factor}: 5.215
{DOI}: 10.3390/ph16020176
{Abstract}: Innovative lipid-modifying agents are valuable resources to improve the control of atherogenic dyslipidemias and reduce the lipid-related residual cardiovascular risk of patients with intolerance or who are not fully responsive to a consolidated standard of care (statins plus ezetimibe). Moreover, some of the upcoming compounds potently affect lipid targets that are thus far considered "unmodifiable". The present paper is a viewpoint aimed at presenting the incremental metabolic and cardiovascular benefits of the emerging lipid-modulating agents and real-life barriers, hindering their prescription by physicians and their assumption by patients, which need to be worked out for a more diffuse and appropriate drug utilization.